Education
About Us
Working with TipRanks
Follow Us
Sakar Healthcare Ltd (IN:SAKAR)
:SAKAR
SAKAR Stock Chart & Stats
₹406.55
-₹0.50(-0.17%)
At close: 4:00 PM EST
₹406.55
-₹0.50(-0.17%)
Day’s Range― - ―
52-Week Range₹210.10 - ₹543.50
Previous CloseN/A
Volume6.75K
Average Volume (3M)19.08K
Market Cap
₹10.45B
Enterprise Value₹12.11B
Total Cash (Recent Filing)₹3.09M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)40.6
Beta0.67
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.61
Shares Outstanding21,949,910
10 Day Avg. Volume18,950
30 Day Avg. Volume19,083
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)1.79
Price to Sales (P/S)2.88
P/FCF Ratio-37.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹605.00Price Target Upside48.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSakar's multi-year revenue expansion (15.2% in 2025) indicates durable demand for its formulations across domestic, export and contract-manufacturing channels. Sustained top-line growth supports fixed-cost absorption, capacity utilization and helps fund product development or marketing over the medium term.
Improving Operating Margins (EBIT)A meaningful lift in EBIT margin demonstrates better operating efficiency or a more profitable product mix. Higher sustainable operating margins strengthen earnings power, create buffer against cost inflation, and improve ability to reinvest in manufacturing scale and regulatory compliance over the next several quarters.
Strong Equity Position And Lower LeverageA high equity ratio and declining debt-to-equity indicate conservative capitalization and reduced leverage risk. This balance-sheet strength provides financial flexibility to fund capex, absorb setbacks in export/regulatory timelines, and limits refinancing pressure, supporting medium-term stability.
Bears Say
Sharp Gross Margin CompressionA dramatic drop in gross margin signals structural pressure from pricing, raw-material inflation or an adverse product mix shift. If persistent, lower gross margins compress operating profits and cash generation, forcing either sustained cost restructuring or higher selling prices that could impair market share.
Negative Free Cash FlowContinued negative free cash flow, even though improving, indicates capital expenditures or working-capital needs outpacing operating cash generation. This constrains self-funded growth, increases reliance on external financing, and limits the firm's ability to deleverage or invest without raising capital.
Relatively Low Net Profit MarginA sub-10% net margin points to thinner retained earnings after operating costs and taxes, limiting internal funding for R&D, capacity expansion or regulatory compliance. Persistently low net margins reduce resilience to cyclical downturns and slow ROE improvement over the medium term.
Sakar Healthcare Ltd News
SAKAR FAQ
What was Sakar Healthcare Ltd’s price range in the past 12 months?
Sakar Healthcare Ltd lowest stock price was ₹210.10 and its highest was ₹543.50 in the past 12 months.
What is Sakar Healthcare Ltd’s market cap?
Sakar Healthcare Ltd’s market cap is ₹10.45B.
When is Sakar Healthcare Ltd’s upcoming earnings report date?
Sakar Healthcare Ltd’s upcoming earnings report date is May 15, 2026 which is in 81 days.
How were Sakar Healthcare Ltd’s earnings last quarter?
Sakar Healthcare Ltd released its earnings results on Feb 05, 2026. The company reported ₹4.606 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.606.
Is Sakar Healthcare Ltd overvalued?
According to Wall Street analysts Sakar Healthcare Ltd’s price is currently Undervalued.
Does Sakar Healthcare Ltd pay dividends?
Sakar Healthcare Ltd does not currently pay dividends.
What is Sakar Healthcare Ltd’s EPS estimate?
Sakar Healthcare Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sakar Healthcare Ltd have?
Sakar Healthcare Ltd has 21,949,910 shares outstanding.
What happened to Sakar Healthcare Ltd’s price movement after its last earnings report?
Sakar Healthcare Ltd reported an EPS of ₹4.606 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 6.088%.
Which hedge fund is a major shareholder of Sakar Healthcare Ltd?
Currently, no hedge funds are holding shares in IN:SAKAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sakar Healthcare Ltd
Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable SVP in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in approximately 22 therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. The company also exports its products to approximately 38 countries, including Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.
SAKAR Stock 12 Month Forecast
Average Price Target
₹605.00
▲(48.81% Upside)
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Kilitch Drugs (India) Limited
―
Medicamen Biotech Limited
―
Nectar Lifesciences Ltd.
―
Venus Remedies Limited
―